Here's Why Boston Scientific (BSX) Fell More Than Broader Market

Company Performance - Boston Scientific (BSX) stock decreased by 9.02% to $62.93, underperforming the S&P 500, which fell by 0.4% [1] - Over the past month, BSX shares have declined by 9.99%, while the Medical sector and S&P 500 lost 10.07% and 7.34%, respectively [1] Earnings Forecast - The upcoming earnings disclosure is expected to show an EPS of $0.8, reflecting a 6.67% increase from the same quarter last year [2] - Revenue is forecasted to be $5.19 billion, indicating an 11.22% rise compared to the previous year [2] Full Year Estimates - For the full year, analysts expect earnings of $3.45 per share and revenue of $22.29 billion, representing increases of 12.75% and 11.04% from last year [3] Analyst Revisions - Recent revisions to analyst forecasts for Boston Scientific are important as they reflect short-term business trends [4] - Upward revisions indicate analysts' positive outlook on the company's operations and profit generation capabilities [4] Zacks Rank and Valuation - The Zacks Rank system, which ranges from 1 (Strong Buy) to 5 (Strong Sell), currently rates Boston Scientific at 3 (Hold) [6] - The Forward P/E ratio for Boston Scientific is 20.03, higher than the industry average of 18.43, indicating a premium valuation [7] PEG Ratio - Boston Scientific has a PEG ratio of 1.07, which is lower than the Medical - Products industry average of 1.52 [8] Industry Ranking - The Medical - Products industry has a Zacks Industry Rank of 170, placing it in the bottom 31% of over 250 industries [8]